Education
About Us
Working with TipRanks
Follow Us
Unity Biotechnology Inc (UBX)
NASDAQ:UBX
RESEARCH TOOLSreports
UBX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.94 - $3.10
Previous CloseN/A
Volume348.46K
Average Volume (3M)174.93K
Market Cap
$28.31M
Enterprise Value$20.16M
Total Cash (Recent Filing)$19.80M
Total Debt (Recent Filing)$26.99M
Price to Earnings (P/E)―
Beta0.11
Next Earnings
May 13, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding16,850,350
10 Day Avg. Volume118,099
30 Day Avg. Volume174,925
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.06
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.96
Forecast
1Y Price Target
$6.67Price Target Upside316.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Unity Biotechnology News
PremiumCompany Announcements
Unity Biotechnology Appoints Dr. Yehia Hashad to Board
PremiumCompany Announcements
Unity Biotechnology Reports 2024 Financial Results and Updates
---
Ownership Overview
10.00% Insiders
4.50% Mutual Funds
0.08% Other Institutional Investors
81.90% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
UBX FAQ
What was Unity Biotechnology Inc’s price range in the past 12 months?
Unity Biotechnology Inc lowest stock price was $0.94 and its highest was $3.10 in the past 12 months.
What is Unity Biotechnology Inc’s market cap?
Unity Biotechnology Inc’s market cap is $28.31M.
When is Unity Biotechnology Inc’s upcoming earnings report date?
Unity Biotechnology Inc’s upcoming earnings report date is May 13, 2025 which is in 63 days.
How were Unity Biotechnology Inc’s earnings last quarter?
Unity Biotechnology Inc released its earnings results on Mar 07, 2025. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.386 by -$0.114.
Is Unity Biotechnology Inc overvalued?
According to Wall Street analysts Unity Biotechnology Inc’s price is currently Undervalued.
Does Unity Biotechnology Inc pay dividends?
Unity Biotechnology Inc does not currently pay dividends.
What is Unity Biotechnology Inc’s EPS estimate?
Unity Biotechnology Inc’s EPS estimate is -0.4.
How many shares outstanding does Unity Biotechnology Inc have?
Unity Biotechnology Inc has 16,850,350 shares outstanding.
What happened to Unity Biotechnology Inc’s price movement after its last earnings report?
Unity Biotechnology Inc reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.386. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Unity Biotechnology Inc?
Currently, no hedge funds are holding shares in UBX
---
Unity Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.67 (316.88% Upside)
$6.67 (316.88% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.7%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.81%
12-Months-Change
Fundamentals
Return on Equity
-148.97%
Trailing 12-Months
Asset Growth
-42.67%
Trailing 12-Months
Company Description
Unity Biotechnology Inc
Unity Biotechnology, Inc. operates as a biotechnology company engaged in the research and development of therapeutics to extend the human health span. The company was founded by Nathaniel David, Jan van Deursen, Judith Campisi and Daohong Zhou in March 2009 and is headquartered in Brisbane, CA.
---
UBX Stock 12 Month Forecast
Average Price Target
$6.67
▲(316.88% Upside)
Technical Analysis
Oncolytics Biotech
―
Sarepta Therapeutics
―
Curis
―
Fate Therapeutics
―
Bioxcel Therapeutics
―
Best Analysts Covering UBX
1 Year
1 Year Success Rate
2/25 ratings generated profit
1 Year Average Return
-45.39%
reiterated a buy rating 22 days ago
Copying Salim Syed's trades and holding each position for 1 Year would result in 8.00% of your transactions generating a profit, with an average return of -45.39% per trade.
---